Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Arcellx, Inc. - Common Stock
(NQ:
ACLX
)
84.14
-0.46 (-0.54%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
368,201
Open
86.10
Bid (Size)
84.14 (51)
Ask (Size)
84.24 (4)
Prev. Close
84.60
Today's Range
83.28 - 86.10
52wk Range
30.88 - 88.66
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Assessing Arcellx: Insights From 7 Financial Analysts
August 09, 2024
Via
Benzinga
ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q2 2024
August 09, 2024
ACLX stock results show that Arcellx beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Performance
YTD
+49.85%
+49.85%
1 Month
+17.02%
+17.02%
3 Month
+56.80%
+56.80%
6 Month
+19.43%
+19.43%
1 Year
+142.83%
+142.83%
More News
Read More
Arcellx Provides Second Quarter 2024 Financial Results and Business Updates
August 08, 2024
From
Arcellx, Inc.
Via
Business Wire
Decoding 8 Analyst Evaluations For Arcellx
July 22, 2024
Via
Benzinga
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
July 04, 2024
Via
InvestorPlace
Exposures
Product Safety
Arcellx Stock Earns Relative Strength Rating Upgrade
June 21, 2024
Via
Investor's Business Daily
The Latest Analyst Ratings For Arcellx
June 18, 2024
Via
Benzinga
Expert Ratings For Arcellx
May 31, 2024
Via
Benzinga
Analyst Expectations For Arcellx's Future
May 14, 2024
Via
Benzinga
7 Biotech Stocks to Put on Your Breakthrough Radar
May 27, 2024
Via
InvestorPlace
ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q1 2024
May 09, 2024
Via
InvestorPlace
Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
May 09, 2024
From
Arcellx, Inc.
Via
Business Wire
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
May 09, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Peering Into Arcellx's Recent Short Interest
April 15, 2024
Via
Benzinga
Arcellx Analysts Boost Their Forecasts After Q4 Results
February 29, 2024
Via
Benzinga
Arcellx Provides First Quarter 2024 Financial Results
May 09, 2024
From
Arcellx, Inc.
Via
Business Wire
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
May 09, 2024
Via
InvestorPlace
Arcellx to Participate in Two Upcoming Investor Conferences
May 07, 2024
From
Arcellx, Inc.
Via
Business Wire
Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference
April 04, 2024
From
Arcellx, Inc.
Via
Business Wire
Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
March 20, 2024
From
Arcellx, Inc.
Via
Business Wire
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
March 07, 2024
Via
Benzinga
The 3 Biotech Stocks That Could Make Your February Unforgettable
February 15, 2024
Via
InvestorPlace
Decoding Bearish Analog And The Warning Signs You Can't Ignore
February 07, 2024
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market
January 16, 2024
Via
InvestorPlace
Exposures
Product Safety
Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024
January 04, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.